Efficacy
SECONDARY
OS was analyzed as a planned secondary endpoint of the trial. At a median follow-up of 20 weeks (range 5–156 weeks), median OS was 4.9 months. OS rates at 13, 26 and 52 weeks were 68%, 44% and 26%, respectively (Fig. 